Cargando…

Proarrhythmia and Oncotherapy: So Much To Be Done!

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Kovacs, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352192/ https://www.ncbi.nlm.nih.gov/pubmed/34396310 http://dx.doi.org/10.1016/j.jaccao.2021.02.001

Ejemplares similares

Drugging SUMOylation for neuroprotection and oncotherapy
por: Bernstock, Joshua D., et al.
Publicado: (2018)

PKM2 in carcinogenesis and oncotherapy
por: He, Xia, et al.
Publicado: (2017)

Proarrhythmia Induced by Propafenone: What is the Mechanism?
por: Femenia, Francisco, et al.
Publicado: (2010)

Transgenic Rabbit Models in Proarrhythmia Research
por: Baczkó, István, et al.
Publicado: (2020)

The Role of Toll-Like Receptors in Oncotherapy
por: Liu, Caiqi, et al.
Publicado: (2019)

“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus
por: Cannon, Laura, et al.
Publicado: (2022)

Reflex and reflective testing: progress, but much still to be done
por: Murphy, Michael J
Publicado: (2021)

So much potential
por: Jenni, Peter
Publicado: (2004)

There’s Much Yet to be Done: Diverse Perspectives on HPV Vaccination
por: Zimet, Gregory D., et al.
Publicado: (2019)

Reflections on the Multidisciplinary Health Force: much done, but more to do
por: Houghton, Frank
Publicado: (2022)

Medical maladies in eating disorders—there is still much work to be done
por: Nitsch, Allison, et al.
Publicado: (2023)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Proarrhythmia in a Patient With Heart Failure on Therapy With Amiodarone
por: Semerdzhieva, Niya E, et al.
Publicado: (2021)

Application of Bioactive Quercetin in Oncotherapy: From Nutrition to Nanomedicine
por: Nam, Ju-Suk, et al.
Publicado: (2016)

Glycogen synthase kinase 3β in tumorigenesis and oncotherapy
por: He, Rui, et al.
Publicado: (2020)

Commentary: The Ross reversal: Should it be done, if so when?
por: Mack, Charles A., et al.
Publicado: (2021)

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias
por: Koike, Hideki, et al.
Publicado: (2016)

Splicing: still so much to learn
por: Krainer, Adrian R.
Publicado: (2015)

There’s So Much More to Cats…
por: Scherk, Margie
Publicado: (2020)

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
por: Polak, Sebastian, et al.
Publicado: (2015)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
por: Xie, Shulan, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy
por: Dai, Xiaofeng, et al.
Publicado: (2023)

Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy
por: Li, Jianmin, et al.
Publicado: (2023)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia
por: Hegyi, Bence, et al.
Publicado: (2021)

Pharmacotherapy-Based Problems in the Management of Diabetes Mellitus: Needs Much More to be Done!
por: Ali, N, et al.
Publicado: (2010)

Declining childhood and adolescent cancer mortality: Great progress but still much to be done
Publicado: (2014)

Good progress in a number of areas of ASRH, but there is much more that needs to be done
por: Akwara, Elsie, et al.
Publicado: (2023)

Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia
por: Ezeani, Martin, et al.
Publicado: (2017)

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy
por: Liu, Hanmeng, et al.
Publicado: (2023)

Dual identity of tumor-associated macrophage in regulated cell death and oncotherapy
por: Shao, Yingying, et al.
Publicado: (2023)

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018)

Lipoprotein (a)—We Know So Much Yet Still Have Much to Learn …
por: Banach, Maciej
Publicado: (2016)

If self‐shading is so bad, why is there so much? Short shoots reconcile costs and benefits
por: de Haldat du Lys, Alexandre, et al.
Publicado: (2022)

Stability of chronic medicines in dosage administration aids. How much have been done?
por: Tan, Joyce Zhen Yin, et al.
Publicado: (2016)

Automated Algorithm for J-T(peak) and T(peak)-T(end) Assessment of Drug-Induced Proarrhythmia Risk
por: Johannesen, Lars, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ue9lf7mfcemdjo6i2a3vp244u